(vianews) - merck and co inc (mrk.pa) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| merck and co inc (mrk.pa) | €103.40 | 2.86% | 34.46% |
| ucb (ucb.br) | €85.82 | 1.61% | 4.81% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. merck and co inc (mrk.pa)
2.86% forward dividend yield and 34.46% return on equity
merck & co., inc. operates as a healthcare company worldwide. it operates through two segments, pharmaceutical and animal health. the pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. the animal health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. the company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. it has collaborations with astrazeneca plc; bayer ag; eisai co., ltd.; ridgeback biotherapeutics lp; and gilead sciences, inc. to jointly develop and commercialize long-acting treatments in hiv. merck & co., inc. was founded in 1891 and is headquartered in rahway, new jersey.
earnings per share
as for profitability, merck and co inc has a trailing twelve months eps of €2.3.
pe ratio
merck and co inc has a trailing twelve months price to earnings ratio of 45.03. meaning, the purchaser of the share is investing €45.03 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 34.46%.volume
today's last reported volume for merck and co inc is 300 which is 33.92% below its average volume of 454.
more news about merck and co inc.
2. ucb (ucb.br)
1.61% forward dividend yield and 4.81% return on equity
ucb sa, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. the company's primary products include cimzia for inflammatory tnf mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; vimpat, keppra, and briviact for epilepsy; neupro for parkinson's disease and restless legs syndrome; nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and zyrtec and xyzal for allergies. it also offers evenity for the treatment of osteoporosis in postmenopausal women; bimzelx for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. in addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; bepranemab to treat alzheimer's disease; and ucb0599 to treat parkinson's disease. further, it engages in contract manufacturing activities. ucb sa has collaboration agreements with amgen, biogen, roche/genentech, novartis, otsuka, and doc.ai. it operates in the united states, japan, germany, rest of europe, spain, france, china, italy, the united kingdom, ireland, belgium, and internationally. the company was incorporated in 1925 and is headquartered in brussels, belgium.
earnings per share
as for profitability, ucb has a trailing twelve months eps of €3.77.
pe ratio
ucb has a trailing twelve months price to earnings ratio of 22.76. meaning, the purchaser of the share is investing €22.76 for every euro of annual earnings.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.81%.sales growth
ucb's sales growth for the current quarter is negative 4.6%.
more news about ucb.